Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

14.08 -0.45 (-3.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,303,071
Open 14.29
Bid (Size) 12.35 (100)
Ask (Size) 15.50 (200)
Prev. Close 14.53
Today's Range 14.02 - 14.52
52wk Range 6.775 - 20.76
Shares Outstanding 144,311,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On ↗
This immuno-driven diagnostics company, known for partnerships with Genentech and Microsoft, just reported a notable insider sale. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
-11.5%
-11.5%
1 Month
+5.2%
+5.2%
3 Month
-20.8%
-20.8%
6 Month
-18.5%
-18.5%
1 Year
+88.0%
+88.0%

More News

Read More
News headline image
Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look ↗
Via The Motley Fool
Topics Regulatory Compliance
Adaptive Biotechnologies (NASDAQ:ADPT) Reports Strong Q4 Revenue Beat and Path to Profitability ↗
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotech (ADPT) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization
Via MarketMinute
News headline image
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗
Via Benzinga
News headline image
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday ↗
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Adaptive Biotechnologies Through 4 Analysts ↗
Via Benzinga

Frequently Asked Questions

Is Adaptive Biotechnologies Corporation - Common Stock publicly traded?
Yes, Adaptive Biotechnologies Corporation - Common Stock is publicly traded.
What exchange does Adaptive Biotechnologies Corporation - Common Stock trade on?
Adaptive Biotechnologies Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Adaptive Biotechnologies Corporation - Common Stock?
The ticker symbol for Adaptive Biotechnologies Corporation - Common Stock is ADPT on the Nasdaq Stock Market
What is the current price of Adaptive Biotechnologies Corporation - Common Stock?
The current price of Adaptive Biotechnologies Corporation - Common Stock is 14.08
When was Adaptive Biotechnologies Corporation - Common Stock last traded?
The last trade of Adaptive Biotechnologies Corporation - Common Stock was at 04/16/26 04:00 PM ET
What is the market capitalization of Adaptive Biotechnologies Corporation - Common Stock?
The market capitalization of Adaptive Biotechnologies Corporation - Common Stock is 2.03B
How many shares of Adaptive Biotechnologies Corporation - Common Stock are outstanding?
Adaptive Biotechnologies Corporation - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.